Immunotherapy最新文献_第10页

A case report of breast cancer recurrence with cystitis: the impact of immune checkpoint inhibitor therapy on the incidence of cystitis. 乳腺癌复发膀胱炎1例：免疫检查点抑制剂治疗对膀胱炎发病率的影响

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-01-01 Epub Date: 2026-01-27 DOI: 10.1080/1750743X.2026.2620589

Jieqing Li, Yingyi Lin

{"title":"A case report of breast cancer recurrence with cystitis: the impact of immune checkpoint inhibitor therapy on the incidence of cystitis.","authors":"Jieqing Li, Yingyi Lin","doi":"10.1080/1750743X.2026.2620589","DOIUrl":"10.1080/1750743X.2026.2620589","url":null,"abstract":"Background: Immune checkpoint inhibitors (ICIs) are essential for advanced breast cancer, particularly triple-negative breast cancer (TNBC) patients. While effective, they may cause immune-related adverse events (irAEs), including rare cases of cystitis with unclear mechanisms. This study reports a cystitis case following ICI therapy in a recurrent breast cancer patient, exploring potential associations.Case presentation: A 51-year-old female with recurrent breast cancer (TNBC-like, IM subtype) following a 10-year disease-free interval underwent treatment with a paclitaxel-based chemotherapy regimen combined with camrelizumab. Three weeks after initiating ICI therapy, urinary frequency, urgency, dysuria, and hematuria developed. Urinalysis showed leukocyte esterase 3+, protein 2+, and occult blood 2+, with negative bacterial and fungal cultures. Bladder wall thickening and mild bilateral hydronephrosis were detected on ultrasound. Symptomatic management, including urinary alkalization and anti-inflammatory therapy, resulted in gradual symptom improvement. After discontinuation of camrelizumab, the patient experienced two episodes of cystitis, both of which resolved following treatment with methylprednisolone, with no further episodes observed during subsequent follow-up.Conclusion: This case highlights a rare presentation of immune-related cystitis associated with ICI therapy in recurrent breast cancer. ICIs may increase cystitis risk through immune-mediated mechanisms, although the underlying pathophysiology remains unclear, warranting further investigation.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"45-50"},"PeriodicalIF":2.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13060044/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146062736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multi-omics insights into gut microbial dysbiosis and metabolic alterations in immune checkpoint inhibitor-induced thrombocytopenia. 免疫检查点抑制剂诱导的血小板减少症中肠道微生物生态失调和代谢改变的多组学研究。

IF 2.3 4区医学

Immunotherapy Pub Date : 2025-12-01 Epub Date: 2026-01-23 DOI: 10.1080/1750743X.2026.2618937

Bei Xu, Peng Liu, Na Yan, Tao Wang, Ling Liu, Yunfeng Cheng

{"title":"Multi-omics insights into gut microbial dysbiosis and metabolic alterations in immune checkpoint inhibitor-induced thrombocytopenia.","authors":"Bei Xu, Peng Liu, Na Yan, Tao Wang, Ling Liu, Yunfeng Cheng","doi":"10.1080/1750743X.2026.2618937","DOIUrl":"10.1080/1750743X.2026.2618937","url":null,"abstract":"Background: Immune checkpoint inhibitors-induced thrombocytopenia (ICIs-TCP) is a rare immune-related adverse events (irAEs). The physiological changes underlying ICIs-TCP remain incompletely elucidated.Methods: We performed multi-omics analysis (gut microbiome, plasma metabolomics/proteomics) comparing microbial/metabolic alterations in cancer patients with (n = 8) and without ICIs-TCP (n = 8). Fecal metagenomic shotgun sequencing was performed to assess microbial composition and function, while plasma metabolomics and proteomics analyses identified systemic metabolic and protein expression changes associated with ICIs-TCP.Results: Patients with ICIs-TCP exhibited distinct gut microbiota profiles, with an increased abundance of Segatella, Prevotella, and Clostridium, alongside a depletion of Bacteroides and Roseburia. Functional analysis revealed significant downregulation of metabolic pathways, including arginine biosynthesis, alanine, aspartate, and glutamate metabolism. Plasma metabolomics identified reduced arginine levels and disruptions in key amino acid and energy metabolism pathways, suggesting systemic arginine depletion. Proteomic analysis further demonstrated down-regulation of folate hydrolase 1 (FOLH1), a key enzyme in glutamate metabolism, implicating metabolic dysregulation in TCP pathogenesis.Conclusion: The depletion of arginine and associated metabolic disruptions are associated with ICIs-TCP and may represent a potential therapeutic target for mitigating TCP risk in patients receiving ICIs.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1231-1239"},"PeriodicalIF":2.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12952268/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146029510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dual-edged therapy: corticosteroids in the era of immunotherapy. 双刃剑疗法：免疫疗法时代的皮质类固醇。

IF 2.3 4区医学

Immunotherapy Pub Date : 2025-12-01 Epub Date: 2026-01-20 DOI: 10.1080/1750743X.2026.2616478

Angelina Lim, Robert Hsu, Jorge Nieva, Fumito Ito

引用次数: 0

Immunotherapy expectations and knowledge in practice and clinical trials: a cross-sectional study. 免疫治疗在实践和临床试验中的期望和知识：一项横断面研究。

IF 2.3 4区医学

Immunotherapy Pub Date : 2025-12-01 Epub Date: 2026-01-13 DOI: 10.1080/1750743X.2026.2616477

Beliz Bahar Karaoğlan, Filiz Çay Şenler

{"title":"Immunotherapy expectations and knowledge in practice and clinical trials: a cross-sectional study.","authors":"Beliz Bahar Karaoğlan, Filiz Çay Şenler","doi":"10.1080/1750743X.2026.2616477","DOIUrl":"10.1080/1750743X.2026.2616477","url":null,"abstract":"Background: There often exist a gap between patient knowledge and expectations about immune checkpoint inhibitors (ICIs). Few studies have directly compared outpatient clinic (OC) patients and clinical trial (CT) participants in this context.Methods: This single-center, cross-sectional study included 124 patients with solid tumors treated with ICIs at Ankara University between July 2024 and February 2025 (76 OC; 48 CT). A structured questionnaire evaluated patients' understanding of ICI mechanisms and side effects, along with their treatment expectations and decision-making preferences.Results: Oncologists were the main source of information for both groups. Although more CT patients reported feeling adequately informed (62.5% vs. 34.2%, p = 0.003), both groups performed similarly poorly on objective knowledge questions. CT patients had significantly higher treatment expectations (91.7% vs. 64.5%, p = 0.001) and greater satisfaction with treatment outcomes (75% vs. 46.1%, p = 0.002). Expectations regarding side effects were comparable. Most patients, regardless of setting, preferred that physicians make decisions about discontinuing ICI therapy.Conclusion: Despite feeling informed, patients often lack accurate knowledge about ICIs. CT participation appears to enhance optimism and satisfaction but not necessarily understanding. These findings emphasize the importance of targeted education to bridge the knowledge-expectation gap and support shared decision-making.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1223-1229"},"PeriodicalIF":2.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12952253/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145965872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cemiplimab in the treatment of cutaneous squamous cell carcinoma. 西米单抗治疗皮肤鳞状细胞癌。

IF 2.3 4区医学

Immunotherapy Pub Date : 2025-12-01 Epub Date: 2026-01-29 DOI: 10.1080/1750743X.2026.2619658

Luke S McLean, Annette M Lim, Danny Rischin

引用次数: 0

A case of immune-related adverse events, thyroid dysfunction, myocarditis with myositis, and myasthenia gravis overlap syndrome following serplulimab administration for lung adenocarcinoma. serpluliumab治疗肺腺癌后出现免疫相关不良事件、甲状腺功能障碍、心肌炎伴肌炎和重症肌无力重叠综合征1例。

IF 2.3 4区医学

Immunotherapy Pub Date : 2025-12-01 Epub Date: 2026-01-22 DOI: 10.1080/1750743X.2026.2619654

Xiaoliang Li, Qi Feng, Yuan Yu, Xudong Zhao, Pengxi Wang, Dafu Tang, Hailiang Yu

{"title":"A case of immune-related adverse events, thyroid dysfunction, myocarditis with myositis, and myasthenia gravis overlap syndrome following serplulimab administration for lung adenocarcinoma.","authors":"Xiaoliang Li, Qi Feng, Yuan Yu, Xudong Zhao, Pengxi Wang, Dafu Tang, Hailiang Yu","doi":"10.1080/1750743X.2026.2619654","DOIUrl":"10.1080/1750743X.2026.2619654","url":null,"abstract":"Background: Serplulimab is an immune checkpoint inhibitor (ICI) that blocks inhibitors, augmenting anti-tumor immunity but also carrying risks of immune-related adverse events (irAEs). While neuromuscular and cardiac toxicities are rare, their co-occurrence can lead to high mortality. In this article, we report a patient with multiorgan irAEs after treatment with chemoimmunotherapy.Case presentation: A 49-year-old man with lung adenocarcinoma developed thyroid dysfunction 3 weeks after initial chemoimmunotherapy (carboplatin, pemetrexed, serplulimab). Following the second cycle, he presented with speech difficulty, bilateral ptosis, dysphagia, fatigue, and elevated creatine kinase (2112 U/L) and troponin T (570 ng/L), suggesting ICI-induced thyroid dysfunction, myocarditis, myositis, and myasthenia gravis overlap syndrome. Brain magnetic resonance imaging was negative. He received methylprednisolone with initial improvement, but troponin elevation recurred after premature steroid discontinuation. Successful treatment was achieved with high-dose methylprednisolone and intravenous immunoglobulin, leading to normalized cardiac markers.Conclusions: The serplulimab-induced multiorgan irAEs necessitates enhanced monitoring, biomarker research, and multidisciplinary collaboration to optimize safety and antitumor efficacy.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1241-1247"},"PeriodicalIF":2.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12952257/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146018435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Protecting patients in the U.S. from the financial burden of cancer immunotherapy: what can be done? 保护美国患者免受癌症免疫治疗的经济负担：可以做些什么？

IF 2.3 4区医学

Immunotherapy Pub Date : 2025-12-01 Epub Date: 2026-01-22 DOI: 10.1080/1750743X.2026.2619143

Kelsey M Owsley, Tatiane Santos, Mika K Hamer

引用次数: 0

Clinical optimization of bexmarilimab as a myeloid checkpoint therapy. bexmarilimab作为骨髓检查点治疗的临床优化。

IF 2.3 4区医学

Immunotherapy Pub Date : 2025-12-01 Epub Date: 2026-01-27 DOI: 10.1080/1750743X.2026.2617035

Mahalakshmi Karthikeyan, Jesper Mickos, Maija Hollmén

引用次数: 0

Evaluating inebilizumab in the treatment of generalized myasthenia gravis. 评价依比利单抗治疗广泛性重症肌无力的疗效。

IF 2.3 4区医学

Immunotherapy Pub Date : 2025-11-01 Epub Date: 2025-11-25 DOI: 10.1080/1750743X.2025.2594349

Olimpia Carbunar

{"title":"Evaluating inebilizumab in the treatment of generalized myasthenia gravis.","authors":"Olimpia Carbunar","doi":"10.1080/1750743X.2025.2594349","DOIUrl":"10.1080/1750743X.2025.2594349","url":null,"abstract":"Myasthenia gravis (MG) is the most common neuromuscular junction disorder. Despite the recent advances in the field, there are still unmet needs. Novel treatments based on new mechanisms of action are now available, including complement inhibitors, neonatal FcRn inhibitors and more recently, B cell-targeted therapies. This review provides a comprehensive overview of inebilizumab, emphasizing its clinical efficacy, safety profile, and potential role in managing MG. Inebilizumab targets CD19 B cells, thereby extending beyond conventional CD20-targeted therapies. Recent results from MINT study suggests that inebilizumab may provide meaningful and sustained disease control, with a potentially favorable safety profile. However, long-term data remains uncertain. Head-to-head comparisons with other B cell therapies, complement inhibitors or FcRn inhibitors are lacking. Patient selection will be critical, with inebilizumab best suited for refractory MG or those who have not responded adequately to existing biologics. As the treatment options for MG expands, choosing the right treatment for the patient will rely on thoroughly evaluating the efficacy, time to achieve minimal symptomatic state, comparative effectiveness, treatment burden, side effects, and cost. Ultimately, data from clinical practice and ongoing phase III trials will be essential to define the best role of inebilizumab in treatment of MG.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1207-1214"},"PeriodicalIF":2.3,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12952260/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145603784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multisystem immune-related adverse events during combined ipilimumab-nivolumab with subsequent disease progression: a case report. 伊匹单抗-纳武单抗联合治疗期间伴随疾病进展的多系统免疫相关不良事件：1例报告

IF 2.3 4区医学

Immunotherapy Pub Date : 2025-11-01 Epub Date: 2025-12-17 DOI: 10.1080/1750743X.2025.2604430

Elsa Jonsdottir, Ivan Arni Robertsson, Agust Hilmarsson, Rafn Benediktsson, Sigurdis Haraldsdottir

{"title":"Multisystem immune-related adverse events during combined ipilimumab-nivolumab with subsequent disease progression: a case report.","authors":"Elsa Jonsdottir, Ivan Arni Robertsson, Agust Hilmarsson, Rafn Benediktsson, Sigurdis Haraldsdottir","doi":"10.1080/1750743X.2025.2604430","DOIUrl":"10.1080/1750743X.2025.2604430","url":null,"abstract":"In this case report we present a 70-year-old patient with metastatic melanoma who was treated with combined ipilimumab-nivolumab. After two cycles, the patient developed concurrent immune checkpoint inhibitor (ICI)-related hypophysitis and colitis that required hospitalization. Despite discontinuation of immunotherapy and initiation of corticosteroids, the patient experienced steroid-refractory colitis, which required readmission. During the following weeks, the patient developed ICI-related polyneuropathy, which was treated with intravenous immunoglobulin (IVIG). After these irAEs, three computed tomography (CT) staging assessments conducted at two-month intervals showed a progressively enlarging hepatic lesion without signs of regression of the disease. The patient subsequently died from progressive disease. This case illustrates an unusual combination of hypophysitis, colitis and neurologic irAEs with a strong immune response, without tumor regression. It emphasizes the critical importance of continuous patient monitoring for new multisystem immune-related adverse events (irAEs), even after ICI discontinuation and start of immunosuppressive treatment.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1189-1195"},"PeriodicalIF":2.3,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12952259/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145767922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0